Journal
EPILEPSIA
Volume 52, Issue 9, Pages 1750-1756Publisher
WILEY
DOI: 10.1111/j.1528-1167.2011.03155.x
Keywords
Epilepsy; Imaging; Guidelines
Categories
Funding
- Lundbeck Inc.
- King Pharmaceuticals
- PRA International, Eisai Inc.
- Marinus Pharmaceuticals, Inc.
- NIH [NINDS] [1R01NS44280-01]
- NIH NICHD [1P30HD40677-01]
- NCRR [1K12RR17613-01]
- NIMH [1 R01 MH065395-01A2]
- CDC-APTR [R-03]
- National Institute for Health Research [NF-SI-0509-10161] Funding Source: researchfish
Ask authors/readers for more resources
Recognition of limited economic resources, as well as potential adverse effects of over testing, has increased interest in evidence-based assessment of new medical technology. This creates a particular problem for evaluation and treatment of epilepsy, which are increasingly dependent on advanced imaging and electrophysiology, since there is a marked paucity of epilepsy diagnostic and prognostic studies that meet rigorous standards for evidence classification. The lack of high quality data reflects fundamental weaknesses in many imaging studies but also limitations in the assumptions underlying evidence classification schemes as they relate to epilepsy, and to the practicalities of conducting adequately powered studies of rapidly evolving technologies. We review the limitations of current guidelines and propose elements for imaging studies that can contribute meaningfully to the epilepsy literature.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available